Preeclampsia, a multisystem progressive pregnancy complication characterized by high blood pressure and organ dysfunction, poses diagnostic challenges due to overlapping symptoms with normal pregnancies. Early screening and diagnosis play a crucial role in managing preeclampsia, as delivery is currently the only cure. The global preeclampsia laboratory testing market is expected to reach a value of US$17,386.1 million and a volume of 1,22,998,000 tests by 2027, growing from US$13,863.3 million in 2022. The market will experience a healthy CAGR of 4.6% from 2022 to 2027, driven by the increasing burden of preeclampsia and advancements in medical technologies.
Developing Countries Pursue Innovative Diagnostics
Preeclampsia is more prevalent in developing countries, with the World Health Organization estimating seven times higher incidence compared to developed nations. Clinical and biochemical tests for preeclampsia are being developed, but reliable and cost-effective screening remains a challenge. Collaborations between companies, research institutes, and universities aim to create affordable diagnostic kits for preeclampsia. Increasing awareness, campaigns by patient advocacy groups, and government initiatives are driving the demand for innovative tests to address the unmet needs in preeclampsia diagnosis.
Novel Biomarkers Improve Precision
The development of novel biomarkers promises to enhance diagnostic accuracy and precision for preeclampsia. These biomarkers can reduce overdiagnosis and underdiagnosis by providing greater accuracy in assessing the conditions severity. For example, cell-free RNA (cfRNA) shows potential in non-invasive diagnostics, although further research is needed to create disease-specific reference databases. Blood tests are estimated to contribute around 41% to the global preeclampsia laboratory testing market in 2021.
Developed Regions Lead, Asia Pacific Shows Growth Potential
Technologically advanced diagnostic laboratories and a strong emphasis on early preeclampsia screening contribute to the dominance of North America and Europe. Europe is expected to exhibit the highest CAGR of 6.2% during the 2022-2027 forecast period due to ongoing research in preeclampsia diagnostics. In contrast, Asia Pacific maintains its growth potential, driven by a large population of women of reproductive age. Low- and middle-income countries in these regions have high growth rates due to increasing preeclampsia incidences and urgent diagnostic needs.
Challenges in Awareness and Fertility Rates
Challenges persist in terms of awareness and the availability of reliable, cost-effective screening tests, especially in developing economies. Lifestyle and therapeutic interventions that lower preeclampsia risk may also hinder the markets growth. Furthermore, declining fertility rates worldwide may reduce the demand for preeclampsia diagnostic tests in the near future.
Key Players Prioritize Research and Collaboration
Leading players in the global preeclampsia laboratory testing market include PerkinElmer Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., F. Roche Hofmann, Progenity, Inc., GestVision, Inc., Metabolomic Diagnostics Ltd., DiabetOmics Inc., DRG INSTRUMENTS GmbH, Lifeassay Diagnostics (Pty) Ltd, and Quidel Corporation. These companies are focusing on research and development and collaborative efforts to strengthen their market position.
Browse Global Preeclampsia Laboratory Testing Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021-2025-[2023 UPDATE Available-Forecast 2023-2030*] (By Test Type, Preeclampsia Type, End User, By Geography, Leading Companies): https://www.fairfieldmarketresearch.com/report/preeclampsia-laboratory-testing-market
Similar Reports:
U.S. Preeclampsia Laboratory Testing Market: https://www.fairfieldmarketresearch.com/report/us-preeclampsia-laboratory-testing-market
Laboratory Filtration Market: https://www.fairfieldmarketresearch.com/report/laboratory-filtration-market
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: [email protected]
This press release first seen on Brilad
COMTEX_440946118/2840/2023-09-26T01:54:35
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Smart Herald journalist was involved in the writing and production of this article.